• Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.
    • Peters MLB, Eckel A, Lietz A, Seguin C, Mueller P, Hur C, Pandharipande PV.
    • Pancreatology. 2022 May 31:S1424-3903(22)00170-3. doi: 10.1016/j.pan.2022.05.003. Epub ahead of print.
    • Genetic testing and its clinical application in prostate cancer management: Consensus statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    • Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam M, Ma ESK, Poon DMC.
    • Front Oncol. 2022 Jun 24;12:962958. doi: 10.3389/fonc.2022.962958.
  • LitAlert ~~ GeneLit.com

    • Surgical Outcome Measures in a Cohort of Patients at High Risk of Breast Cancer Treated by Bilateral Risk Reducing Mastectomy and Breast Reconstruction.
    • Gandhi A, Duxbury P, Clancy T, Lalloo F, Wisely JA, Kirwan CC, Foden P, Stocking K, Howell A, Evans DG.
    • Plast Reconstr Surg. 2022 Jun 24. doi: 10.1097/PRS.0000000000009383. Epub ahead of print.
    • Physical Activity in Young BRCA Carriers and Reduced Risk of Breast Cancer.
    • Bucy AM, Valencia CI, Howe CL, Larkin TJ, Conard KD, Anderlik EW, Valdivi SI, Bea JW.
    • Am J Prev Med. 2022 Jun 20:S0749-3797(22)00246-X. doi: 10.1016/j.amepre.2022.04.022. Epub ahead of print.
    • Review
  • LitAlert ~~ GeneLit.com

    • Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes.
    • Ardeshna DR, Rangwani S, Cao T, Pawlik TM, Stanich PP, Krishna SG.
    • Biomedicines. 2022 Jun 22;10(7):1475. doi: 10.3390/biomedicines10071475.
    • What Chris Evert’s Story Can Teach the World about Genetic Testing.
    • Matloff ET.
    • FORCE. Blog. 2022 Jun 22.
    • Psychological and health behaviour outcomes following multi-gene panel testing for hereditary breast and ovarian cancer risk: a mini-review of the literature.
    • Carlsson L, Thain E, Gillies B, Metcalfe K.
    • Hered Cancer Clin Pract. 2022 Jun 22;20(1):25. doi: 10.1186/s13053-022-00229-x.
  • LitAlert ~~ GeneLit.com

    • Cost-effectiveness of BRCA 1/2 genetic test and preventive strategies using real-world data from an upper-middle income country.
    • Lourenção M, Correa Galendi JS, HD, Antoniazzi AP, Grasel R, Carvalho AL, Mauad EC, Oliveira JH, Reis RM, Mandrik O, Palmero EI.
    • Front Oncol. 2022 Jun 20;12:951310. doi: 10.3389/fonc.2022.951310.
    • A systematic literature review of the management, oncological outcomes and psychosocial implications of male breast cancer.
    • Rutherford CL, Goodman D, Lannigan A.
    • Eur J Surg Oncol. 2022 Jun 10:S0748-7983(22)00488-7. doi: 10.1016/j.ejso.2022.06.004. Epub ahead of print.
    • Review
    • Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    • Graffeo R, Rana HQ, Conforti F, Bonanni B, Cardoso MJ, Paluch-Shimon S, Pagani O, Goldhirsch A, Partridge AH, Lambertini M, Garber JE.
    • Breast. 2022 Jun 18:S0960-9776(22)00104-7. doi: 10.1016/j.breast.2022.06.003. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Surveillance mammography after treatment for male breast cancer.
    • Yadav S, Sangaralingham L, Payne SR, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Freedman RA, Khanani S, Couch FJ, Vachon C, Shah N, Leon-Ferre RA, Ruddy KJ.
    • Breast Cancer Res Treat. 2022 Jun 17. doi: 10.1007/s10549-022-06645-w. Epub ahead of print.
    • ASO Author Reflections: Sentinel Lymph Node Biopsy in BRCA1/2 Germline Pathogenic Variant Carriers Undergoing Risk-Reducing Mastectomy.
    • Ferroum A, Wong SM.
    • Ann Surg Oncol. 2022 Jun 16. doi: 10.1245/s10434-022-12013-1. Epub ahead of print.
    • Commentary
    • The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival.
    • Dbouk M, Katona BW, Brand RE, Chak A, Syngal S, Farrell JJ, Kastrinos F, Stoffel EM, Blackford AL, Rustgi AK, Dudley B, Lee LS, Chhoda A, Kwon R, Ginsberg GG, Klein AP, Kamel I, Hruban RH, He J, Shin EJ, Lennon AM, Canto MI, Goggins M.
    • J Clin Oncol. 2022 Jun 15:JCO2200298. doi: 10.1200/JCO.22.00298. Epub ahead of print.
    • Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
    • Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, Papaikonomou K, Jones L, Herzog C, Pashayan N, Simões BM, Clarke RB, Evans DG, Ghezelayagh TS, Ponandai-Srinivasan S, Boggavarapu NR, Lalitkumar PG, Howell SJ, Risques RA, Rådestad AF, Dubeau L, Gemzell-Danielsson K, Widschwendter M.
    • Genome Med. 2022 Jun 15;14(1):64. doi: 10.1186/s13073-022-01063-5.

    EudraCT number: 2009-009014-40: Pre-treatment with Mifepristone prior to Mirena insertion for optimizing bleeding pattern in pre-menopausal women. (EU Clinical Trials Register)

    Identifier: NCT01898312: BRCA1/2 and Effect of Mifepristone on the Breast. (ClinicalTrials.gov)

    EudraCT number: 2015-001587-19: A pilot prevention study of the effects of the anti-progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk. (EU Clinical Trials Register)

    • Scene memory and hippocampal volume in middle-aged women with early hormone loss.
    • Gervais NJ, Gravelsins L, Brown A, Reuben R, Karkaby L, Baker-Sullivan E, Mendoza L, Lauzon C, Almey A, Foulkes WD, Bernardini MQ, Jacobson M, Velsher L, Rajah MN, Olsen RK, Grady C, Einstein G.
    • Neurobiol Aging. 2022 May 13;117:97-106. doi: 10.1016/j.neurobiolaging.2022.05.003. Epub ahead of print.